Interestingly, the migratory capacity of CD209+/CD14+ dendritic cells has been shown to be significantly inhibited by a JAK/STAT pathway inhibitor (tofacitinib) used in the treatment of various autoimmune diseases [49]. Here, CD14 is linked to autoimmune disease.